相似文献
1
In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae.
Antimicrob Agents Chemother. 2014 Dec;58(12):7595-6. doi: 10.1128/AAC.03920-14. Epub 2014 Oct 6.
2
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae.
Antimicrob Agents Chemother. 2014;58(3):1800-1. doi: 10.1128/AAC.02263-13. Epub 2013 Dec 23.
3
In vitro antibacterial activity of AZD0914 against human Mycoplasmas and Ureaplasmas.
Antimicrob Agents Chemother. 2015;59(6):3627-9. doi: 10.1128/AAC.04945-14. Epub 2015 Mar 30.
4
In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae.
Antimicrob Agents Chemother. 2004 May;48(5):1885-6. doi: 10.1128/AAC.48.5.1885-1886.2004.
5
In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.
Antimicrob Agents Chemother. 2003 Mar;47(3):1135-6. doi: 10.1128/AAC.47.3.1135-1136.2003.
6
Multidrug-Resistant Neisseria gonorrhoeae Isolates from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914).
Antimicrob Agents Chemother. 2015 Oct 19;60(1):621-3. doi: 10.1128/AAC.01211-15. Print 2016 Jan.
7
In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria.
Antimicrob Agents Chemother. 2015 Jan;59(1):467-74. doi: 10.1128/AAC.04124-14. Epub 2014 Nov 10.
8
In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae.
Antimicrob Agents Chemother. 2010 Mar;54(3):1358-9. doi: 10.1128/AAC.01343-09. Epub 2009 Dec 28.
9
Activity of Omadacycline against .
Antimicrob Agents Chemother. 2019 Jan 29;63(2). doi: 10.1128/AAC.01907-18. Print 2019 Feb.
10
In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae.
Antimicrob Agents Chemother. 1993 Sep;37(9):1746-8. doi: 10.1128/AAC.37.9.1746.
引用本文的文献
1
Thorough QT Study To Evaluate the Effect of Zoliflodacin, a Novel Therapeutic for Gonorrhea, on Cardiac Repolarization in Healthy Adults.
Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0129221. doi: 10.1128/AAC.01292-21. Epub 2021 Oct 4.
2
High susceptibility to the first-in-class spiropyrimidinetrione zoliflodacin among consecutive clinical isolates from Thailand (2018) and South Africa (2015-2017).
Antimicrob Agents Chemother. 2019 Sep 9;63(12). doi: 10.1128/AAC.01479-19. Epub 2019 Sep 23.
3
Activity of Omadacycline against .
Antimicrob Agents Chemother. 2019 Jan 29;63(2). doi: 10.1128/AAC.01907-18. Print 2019 Feb.
4
Aminomethyl Spectinomycins as Therapeutics for Drug-Resistant Gonorrhea and Chlamydia Coinfections.
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.00325-18. Print 2018 May.
5
Multidrug-resistant gonorrhea: A research and development roadmap to discover new medicines.
PLoS Med. 2017 Jul 26;14(7):e1002366. doi: 10.1371/journal.pmed.1002366. eCollection 2017 Jul.
6
Amphipathic β2,2-Amino Acid Derivatives Suppress Infectivity and Disrupt the Intracellular Replication Cycle of Chlamydia pneumoniae.
PLoS One. 2016 Jun 9;11(6):e0157306. doi: 10.1371/journal.pone.0157306. eCollection 2016.
7
Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin.
Nat Commun. 2015 Dec 7;6:10048. doi: 10.1038/ncomms10048.
8
In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens.
Antimicrob Agents Chemother. 2015 Oct;59(10):6053-63. doi: 10.1128/AAC.01016-15. Epub 2015 Jul 20.
9
High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014.
Antimicrob Agents Chemother. 2015 Sep;59(9):5220-5. doi: 10.1128/AAC.00786-15. Epub 2015 Jun 15.
10
In vitro antibacterial activity of AZD0914 against human Mycoplasmas and Ureaplasmas.
Antimicrob Agents Chemother. 2015;59(6):3627-9. doi: 10.1128/AAC.04945-14. Epub 2015 Mar 30.
本文引用的文献
1
High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea.
Antimicrob Agents Chemother. 2014 Sep;58(9):5585-8. doi: 10.1128/AAC.03090-14. Epub 2014 Jun 30.
2
Treatment of chlamydial infections.
Expert Opin Pharmacother. 2012 Mar;13(4):545-52. doi: 10.1517/14656566.2012.658776. Epub 2012 Feb 9.
3
Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia.
Antimicrob Agents Chemother. 1998 Jan;42(1):194-6. doi: 10.1128/AAC.42.1.194.
4
Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate.
Pediatr Infect Dis J. 1995 Jun;14(6):471-7. doi: 10.1097/00006454-199506000-00002.
5
Use of HEp-2 cells for improved isolation and passage of Chlamydia pneumoniae.
J Clin Microbiol. 1992 Aug;30(8):1968-71. doi: 10.1128/jcm.30.8.1968-1971.1992.
Zotero 插件